## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.9% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($336.14)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Cencora to Acquire TPG’s Equity Stake in OneOncology, Strengthening Specialty Care Platform**
- Source: Digital Health News | 20251216T110814 | Bullish | Relevance: 100%
- Cencora has announced a definitive agreement to acquire TPG's equity stake in OneOncology, a national platform supporting independent oncology practices. This acquisition is set to accelerate OneOncology's growth by expanding technology capabilities, clinical innovation, and shared services. Both Cencora and TPG expressed confidence that this move will strengthen specialty care and continue OneOncology's success in delivering accessible and innovative oncology care.

**2. Cencora Should See Double-Digit Long-term EPS Growth from Market Growth and Specialty Investments**
- Source: Morningstar | 20251215T200841 | Bullish | Relevance: 100%
- Cencora, a leading pharmaceutical wholesaler, is projected to achieve double-digit long-term EPS growth due to overall market expansion and strategic investments in specialty products. The company, alongside Cardinal Health and McKesson, forms an oligopoly that controls over 90% of the US drug distribution market, ensuring a strong competitive position. Recent moves, including the OneOncology investment, are seen as strategically sound for sustained growth.

**3. Cencora Moves To Take Full Control Of OneOncology**
- Source: Finimize | 20251215T160826 | Bullish | Relevance: 100%
- Cencora is acquiring nearly all of OneOncology for $5 billion, deepening its involvement in the growing US cancer care market. This move transitions Cencora from a minority to a controlling stake, aiming for long-term adjusted earnings growth despite initial neutrality. The deal signifies Cencora’s commitment to specialized healthcare and accelerates consolidation within the cancer care landscape.

**4. Cencora to buy majority of OneOncology's outstanding equity**
- Source: Axios | 20251215T160758 | Bullish | Relevance: 100%
- Cencora plans to acquire most of OneOncology's outstanding equity that it doesn't already own, including shares from TPG, for roughly $5 billion. This acquisition values the cancer practice network OneOncology at approximately $7.4 billion.

**5. Cencora stock price target raised to $420 from $400 at Evercore ISI**
- Source: Investing.com | 20251215T150826 | Bullish | Relevance: 100%
- Evercore ISI has increased its price target for Cencora Inc (NYSE:COR) to $420 from $400, maintaining an Outperform rating, following Cencora's strategic acquisition of the remaining stake in OneOncology. This move is seen as a "prudent use of capital" that is expected to be EPS neutral initially before contributing positively by mid-fiscal year 2027, leading to an upward revision of Cencora's long-term guidance. Other firms like TD Cowen, UBS, and Leerink Partners have also raised their price targets for Cencora, reflecting a positive analyst sentiment regarding the company's financial health, growth, and earnings potential.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.92 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $68.0B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.92 |
| Forward P/E | 17.9 |
| Current P/E | 19.9 |
| YoY Growth | 10.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -7.8% to -0.9% (+6.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.9pp (needs >4.0% for momentum thesis). MRS_5 turning positive (3.5%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.16x) but short-term weakness (below SMA20). MACD histogram bearish (-1.92), momentum weakening. RSI neutral at 52. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.86% (CS: 28) | Neutral |
| RSI_14 | 52.1 | Neutral |
| MACD Histogram | -1.92 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.021x | Above |
| vs SMA200 | 1.162x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $350.32
- **Stop Loss:** $336.14 (4.0% risk)
- **Target:** $364.50 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 84
- **Position Value:** $29,426.88
- **Portfolio %:** 29.43%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*